Under construction – not a live service

Skip to content

Frontlight Research

Institution

Essen University Hospital

Essen, GermanyhealthcareWebsite

Also known as: Universitätsklinikum Essen

474running trials
194closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
2025-522563-15-00· Phase 2/3· Source
Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
NCT07825064· Phase 2· Source
Not yet recruiting
Decompressive Craniectomy After Aneurysmal Subarachnoid Hemorrhage (DECIDE-SAH)
NCT07872774· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· Phase 3· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Source
Recruiting
Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
2026-526026-40-00· Phase 2/3· Source
Not yet recruiting
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
2024-518348-19-00· Phase 1· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Source
Recruiting
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940· Phase 1/2· Source
Not yet recruiting
A study of benfo‑oxythiamine added to Pluvicto® in adults with advanced prostate cancer whose disease is stable after two prior Pluvicto® cycles
2026-527059-25-00· Phase 1/2· Source
Recruiting
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
NCT07700979· Phase 3· Source
Recruiting
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
NCT07860047· Phase 2· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· Source
Recruiting
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
NCT07711002· Phase 3· Source
Not yet recruiting
Health Behaviour and Readiness to Change After Myocardial Infarction: A Cross-sectional Survey
NCT07785921· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Source
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790· Phase 3· Source
Not yet recruiting
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00· Phase 2· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242· Phase 3· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Source
Not yet recruiting
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
NCT07561645· Phase 2· Source
Not yet recruiting
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
NCT07178730· Phase 3· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141· Phase 3· Source
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· Source
Not yet recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
2026-525883-17-00· Phase 3· Source
Not yet recruiting
A Study to Access Activity and Safety with SAR445399 Compared with Placebo in Participants Aged 18 to 80 Years of Age with Non-Cystic Fibrosis Bronchiectasis
2025-523403-29-00· Phase 2· Source
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
2025-524336-19-00· Phase 3· Source
Recruiting
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· Phase 3· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00· Phase 3· Source
Not yet recruiting
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
NCT07553650· Source
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241· Phase 3· Source
Not yet recruiting
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· Phase 3· Source
Not yet recruiting
PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure
2026-526261-14-00· Phase 2· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· Source
Recruiting
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
2025-522138-29-00· Phase 2· Source
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· Phase 3· Source
Recruiting
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00· Phase 1/2· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Source
Recruiting
PREFer
NCT06916416· Phase 2· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
2025-524014-29-00· Phase 3· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· Source
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· Phase 3· Source
Recruiting
Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
2025-521911-38-00· Phase 1/2· Source
Not yet recruiting
Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).
2025-523672-23-00· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Completed
A Study Evaluating BFB759 in Atopic Dermatitis
2025-521624-30-00· Phase 2· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Source
Recruiting
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07160634· Phase 3· Source
Completed
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
NCT07238322· Source
Completed
Neoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)
2024-514386-19-00· Phase 1· Source
Completed
Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection
2024-519856-94-00· Phase 2· Source
Completed
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE)
2024-517561-16-00· Phase 2· Source
Recruiting
Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB)
2024-515847-47-00· Phase 2· Source
Completed
A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
NCT06682806· Phase 2· Source
Completed
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
2024-512505-66-00· Phase 2/3· Source
Completed
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
2024-512670-10-00· Phase 1/2· Source
Completed
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
2023-508998-85-00· Phase 1· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Source
Completed
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers
2023-507674-41-00· Phase 1· Source
Active, not recruiting
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884· Phase 2· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411· Phase 3· Source
Completed
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
NCT06447506· Phase 2· Source
Completed
A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)
2023-506240-16-00· Phase 1/2· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Source
Completed
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
NCT06431763· Phase 4· Source
Completed
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
NCT05808764· Phase 2· Source
Recruiting
Sacituzumab Govitecan in Metastatic Colorectal Cancer
NCT06243393· Phase 2/3· Source
Completed
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis
NCT05999799· Phase 2· Source
Active, not recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
NCT06216158· Phase 3· Source
Active, not recruiting
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
NCT06004661· Phase 2· Source
Completed
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· Phase 3· Source
Completed
PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
NCT06247163· Source
Completed
Adaptive Radiotherapy in Patients With Gynecological Tumors
NCT06230549· Source
Completed
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma
NCT06018129· Phase 1/2· Source
Completed
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (Morpheus-Neo HCC)
2022-502840-11-00· Phase 1/2· Source
Completed
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer
NCT05724602· Phase 2· Source
Completed
Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors
NCT06214611· Source
Active, not recruiting
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579· Phase 1· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· Source
Completed
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
NCT05800964· Phase 1· Source
Completed
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT06036836· Phase 2· Source
Completed
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
2022-502787-20-00· Phase 2· Source
Completed
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
NCT05794139· Phase 2· Source
Completed
Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock
NCT06006754· Source
Completed
Clinical trial of MK-7648A in adults and children with skin cancer
NCT05665595· Phase 3· Source
Completed
Craniosacral Therapy as a Self-help Strategy for Patients With Chronic Non-specific Back Pain
NCT04199091· Source
Completed
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05672199· Phase 2· Source
Completed
Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
NCT05882357· Phase 3· Source
Completed
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors
2022-500540-38-00· Phase 1· Source
Completed
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT05767346· Phase 3· Source
Completed
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
NCT05938387· Phase 1· Source
Completed
Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).
NCT06125808· Phase 2· Source
Completed
A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma
2022-501423-25-00· Phase 1/2· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 02na8dn90 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Essen University Hospital: trials and research groups – Frontlight Research